Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib

Rampotas, Alexandros; Carter-Brzezinski, Luke; Somervaille, Tim C; Forryan, James; Panitsas, Fotios P; Harrison, Claire N; Witherall, Ruth; Innes, Andrew J; Wallis, Louise; Butt, Nauman M; Psaila, Bethan; Mead, Adam J; Carter, Matthew; Godfrey, Anna L; Laing, Heather; Garg, Mamta; Francis, Sebastian; Ewing, Joanne; Teh, Chun Huat; Cowan, Hannah B; Dyer, Peter; McConville, Conal; Wadelin, Frances; Ali, Sahra; McGregor, Andrew; Kulakov, Elizabeth; McLornan, Donal P; Lambert, Jonathan

Abstract

Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

Citation

Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C, Witherall R, Innes AJ, Wallis L, Butt NM, Psaila B, Mead AJ, Carter M, Godfrey AL, Laing H, Garg M, Francis S, Ewing J, Teh CH, Cowen HB, Dyer P, McConville C, Wadelin F, Sahra A, McGregor A, Kulakov E, McLornan DP, Lambert J. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024 Jan 11;143(2):178-182. doi: 10.1182/blood.2023022345.

Type

Correspondence